
    
      This is a multi-center randomized study of three doses of radiation (assigned 1:1:1)
      delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal
      neovascularization (CNV) secondary to wet (exudative) AMD. Each participant receives a single
      dose of radiation delivered by one-time only brachytherapy. Participants are followed for
      three years after the radiation treatment.
    
  